Win Advisors Inc. Purchases Shares of 6,686 Biogen Inc. (NASDAQ:BIIB)

Win Advisors Inc. purchased a new stake in Biogen Inc. (NASDAQ:BIIB) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 6,686 shares of the biotechnology company’s stock, valued at approximately $1,022,000.

Other large investors also recently made changes to their positions in the company. Inspire Trust Co. N.A. increased its stake in shares of Biogen by 58.5% in the third quarter. Inspire Trust Co. N.A. now owns 10,900 shares of the biotechnology company’s stock valued at $2,113,000 after purchasing an additional 4,025 shares during the period. Assenagon Asset Management S.A. boosted its holdings in shares of Biogen by 0.3% in the fourth quarter. Assenagon Asset Management S.A. now owns 43,460 shares of the biotechnology company’s stock valued at $6,646,000 after acquiring an additional 111 shares in the last quarter. Centre Asset Management LLC boosted its holdings in shares of Biogen by 7.7% in the fourth quarter. Centre Asset Management LLC now owns 51,530 shares of the biotechnology company’s stock valued at $7,880,000 after acquiring an additional 3,698 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Biogen by 1.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 913,029 shares of the biotechnology company’s stock valued at $176,982,000 after acquiring an additional 12,319 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in shares of Biogen by 3.2% in the third quarter. Principal Financial Group Inc. now owns 168,631 shares of the biotechnology company’s stock valued at $32,687,000 after acquiring an additional 5,270 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Stock Performance

NASDAQ BIIB opened at $142.49 on Wednesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.26 and a quick ratio of 0.80. The firm has a market capitalization of $20.76 billion, a price-to-earnings ratio of 12.87, a P/E/G ratio of 1.66 and a beta of -0.08. The company’s fifty day moving average is $150.47 and its two-hundred day moving average is $177.77. Biogen Inc. has a 52-week low of $139.71 and a 52-week high of $246.44.

Wall Street Analyst Weigh In

BIIB has been the subject of several recent analyst reports. Jefferies Financial Group cut shares of Biogen from a “buy” rating to a “hold” rating and decreased their price objective for the company from $250.00 to $180.00 in a report on Monday, December 9th. Oppenheimer decreased their price objective on shares of Biogen from $270.00 to $255.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. JPMorgan Chase & Co. reduced their target price on shares of Biogen from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Monday, November 4th. HC Wainwright restated a “buy” rating and set a $300.00 target price on shares of Biogen in a report on Thursday, October 31st. Finally, Wells Fargo & Company reduced their target price on shares of Biogen from $190.00 to $165.00 and set an “equal weight” rating for the company in a report on Friday, January 10th. Sixteen investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $228.80.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.